Hepatic artery infusion (HAI) of oxaliplatin (Ox) as third and fourth-line therapy for patients with hepatic metastases (M) from colorectal cancer (CRC) pretreated with systemic Ox

Hella Gollasch(Helios Hospital Berlin-Buch), Albrecht Kretzschmar(Roche (Switzerland)), C. Stroszczynski(Helios Hospital Berlin-Buch), Isrid Sturm(Helios Hospital Berlin-Buch), P. Thuss-Patience, Bernhard Gebauer(Charité - Universitätsmedizin Berlin), Daniel Pink(Universitätsmedizin Greifswald)

Journal of Clinical Oncology

July 15, 2004

10.1200/jco.2004.22.90140.3695

Cited by 3

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

|European Journal of Cancer|2011|615

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

|Annals of Oncology|2009|534

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group

|Journal of Clinical Oncology|2007|281

Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial

|Annals of Oncology|2005|223